Chemistry:Fuzuloparib

From HandWiki

Fuzuloparib (trade name AiRuiYi) is a pharmaceutical drug for the treatment of ovarian cancer.[1] It is approved for use in China.[2] It is an inhibitor of the poly (ADP-ribose) polymerase (PARP) enzyme.[3]

It is also being studied for its potential use for the treatment of pancreatic, breast, prostate, and lung cancer.[2]

References

  1. ↑ "Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective". Journal of Gynecologic Oncology 33 (6). November 2022. doi:10.3802/jgo.2022.33.e86. PMID 36335989. 
  2. ↑ 2.0 2.1 "Fuzuloparib: First Approval". Drugs 81 (10): 1221–1226. July 2021. doi:10.1007/s40265-021-01541-x. PMID 34118019. 
  3. ↑ "Fuzuloparib - Jiangsu HengRui Medicine". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800043626. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Fuzuloparib&oldid=4243263"